

AGM Results

Dublin, London | 11 May 2022

Uniphar plc is pleased to announce that at the Annual General Meeting held at 11.00 a.m. today, 11 May 2022, each of the resolutions set out in the Notice of Annual General Meeting circulated to shareholders and made available on the Company's website, www.uniphar.ie, were duly passed without amendment.

Details of votes cast are set out below:

	RESOLUTION	TOTAL	FOR	%	AGAINST	%	ABSTAIN
1	Financial Statements and Reports	139,441,694	139,441,694	100	0	0.00	147,705
2	Final Dividend of €2.9m	139,589,399	139,589,399	100	0	0.00	0
3(a)	Re-elect Ger Rabbette	139,589,399	135,469,357	97.05	4,120,042	2.95	0
3(b)	Re-elect Tim Dolphin	139,589,399	138,606,558	99.30	982,841	0.70	0
3(c)	Re-elect Paul Hogan	139,589,399	130,828,345	93.72	8,761,054	6.28	0
3(d)	Re-elect Sue Webb	139,589,399	135,343,699	96.96	4,245,700	3.04	0
3(e)	Re-elect Jeff Berkowitz *	139,589,399	110,242,453	78.98	29,346,946	21.02	0
3(f)	Re-elect Jim Gaul	139,589,399	132,497,099	94.92	7,092,300	5.08	0
3(g)	Re-elect Liz Hctor	139,589,399	135,027,189	96.73	4,562,210	3.27	0
3(h)	Re-elect Maurice Pratt	139,589,399	131,537,248	94.23	8,052,151	5.77	0
4	Remuneration of Auditors	85,749,400	74,945,801	87.40	10,803,599	12.60	53,839,999
5	Allot relevant securities	139,589,399	134,987,663	96.70	4,601,736	3.30	0
6	Disapplication of pre-emption rights in specified circumstances	139,589,399	139,589,399	100	0	0	0
7	Disapplication of pre-emption rights in additional circumstances	139,589,399	139,589,399	100	0	0	0
8	Authorise market purchases of the Company's Ordinary Shares	138,858,398	138,858,398	100	0	0	731,001
9	Re-issuance of Treasury Shares	139,589,399	139,589,399	100	0	0	0
10	Amendment of the Company's Articles of Association to provide for annual retirement of all Directors	139,589,399	139,589,399	100	0	0	0

*The Board notes that Resolution 3(e) passed with a majority of less than 80% (receiving votes in favour of 78.98%). In accordance with provision 4 of the UK Corporate Governance Code (the "**Code**"), the Board confirms that it will engage with shareholders to understand and discuss the reasons behind the proxies received against this resolution. An update on the views received from shareholders and actions taken will be provided within six months of the AGM, in accordance with the Code.

--- ENDS ---

For further details contact:

Uniphar +353 (0) 1 428 7777

Seamus Egan
Head of Corporate Development and IR investor.relations@Uniphar.ie

Davy +353 (0) 1 679 6363
(Joint Corporate Broker, Nominated Adviser and Euronext Growth Adviser)

Barry Murphy
Niall Gilchrist
Lauren O'Sullivan

RBC Capital Markets (Joint Corporate Broker) +44 (0) 20 7653 4000

Jonathan Hardy
Jamil Miah

Stifel Nicolaus Europe Limited (Joint Corporate Broker) +44 (0) 20 7710 7600

Matt Blawat
Ben Maddison
Francis North

Q4 PR +353 (0) 1 475 1444 or
(Public Relations Adviser to Uniphar) +353 87 235 6461

Iarla Mongey

About Uniphar plc

Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. The Group is active in Ireland, the UK, the Benelux, the Nordics, Germany, and the US.

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.

Commercial & Clinical

In Commercial & Clinical, the Group provides outsourced sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers. Active in Ireland, the UK, the Benelux, the Nordics, Germany and the US, the Group is growing with its clients to provide pan-European solutions, with a bespoke offering in the US. Uniphar has built fully integrated digitally enabled customer centric solutions that are supported by our highly experienced and clinically trained teams, leveraging our digital technology and insights which allows us to deliver consistently exceptional outcomes for our clients.

Product Access

In Product Access, the Group is growing two distinct service offerings: 1) "On Demand", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.

Supply Chain & Retail

Uniphar is an established market leader in Ireland with c. 53% market share in the wholesale/hospital market, supported by a network of 378 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are also utilised for the benefit of Commercial & Clinical and Product Access.